RxDoctor Payments Data

Joseph Adinaro, MD

Cardiovascular Disease · Williamsburg, VANPI 1598842791

Payments from drug & device makers

$3,327in general payments, 2019–2025

Across 119 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$2K
  • Irhythm Technologies, Inc.$183
  • Novartis$158
  • Akcea Therapeutics, Inc.$125
  • Pfizer$124
  • Boehringer Ingelheim$90
  • plus $519 from 12 others

What the payments were for

  • Food & beverage$3,324100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,327 in reported general payments places this provider in the 60th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$237,841
Medicare patients
1,890
Services billed
5,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban650$868,561
XareltoRivaroxaban111$144,715
MultaqDronedarone Hcl65$107,973
EntrestoSacubitril/Valsartan74$98,079
JardianceEmpagliflozin50$55,598
Repatha SureclickEvolocumab17$23,517
FarxigaDapagliflozin Propanediol17$16,765
Dofetilide26$12,415
Metoprolol Succinate753$8,864
Losartan Potassium412$4,080
Nebivolol Hcl63$3,920
Atorvastatin Calcium420$3,883
Carvedilol383$3,079
Diltiazem 24hr Er (Cd)Diltiazem Hcl111$2,700
Propranolol Hcl ErPropranolol Hcl41$2,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$868,561650 claims
Johnson & JohnsonXarelto$46$144,715111 claims
NovartisEntresto$158$98,07974 claims
Boehringer IngelheimJardiance$90$55,59850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →